Discovery & history

• Why CJC-1295 is really two different drugs (DAC vs no-DAC)
• How a maleimide and albumin turn a minutes-long peptide into a week-long one
• What the one ConjuChem trial program actually showed, and where it stopped
• How to read community stacking and dosing claims critically

1. 01 Discovery & history One name, two very different molecules free
2. 02 Chemistry & structure Four swaps and a hook: the molecule in detail paid
3. 03 The DAC albumin trick How a chemical hook borrows a week of half-life paid
4. 04 The GH and IGF-1 axis One receptor upstream, a cascade downstream paid
5. 05 Pulsatile versus sustained GH A rhythm amplified, or a baseline raised paid
6. 06 The clinical evidence One short program, read honestly paid
7. 07 The CJC + ipamorelin stack Two receptors, one coordinated push paid
8. 08 Compared to other GH-axis drugs One family, several very different tools paid
9. 09 Product quality & regulation The label problem, and the legal reality paid
10. 10 Dosing & Administration What the community reports, read critically paid
11. 11 Safety & Side Effects Real short-term signals, large long-term unknowns paid
12. 12 Final Exam & Certification Pass the final exam to earn your certificate of completion. Exam

The story of CJC-1295 is the story of a single engineering problem: natural GHRH is broken down rapidly in plasma, so making it useful meant making it last. ConjuChem built the albumin-binding version for that. A second version without the albumin linker later appeared on the gray market; it first reached the literature in 2010, in the analysis of a preparation Norwegian authorities had seized in 2009. The timeline marks the key beats.

Read this as a story that stops early. CJC-1295 reached pharmacology studies in healthy adults and one patient trial that was terminated, then ConjuChem withdrew it from clinical trials, and today it is sold online "for research use only". Almost everything claimed for it since goes beyond that small published base.

Strip away the branding and CJC-1295 is GHRH(1-29), the first 29 building blocks of natural GHRH, a stretch FDA describes as a fully functional sequence of the hormone, carrying four small amino-acid swaps. The DAC version adds one more piece: a lysine carrying a chemical linker that grabs albumin. The derivation shows the natural 29-residue core the drug keeps, and the numbers card summarizes the molecule at a glance.

Those four swaps are not cosmetic. FDA records a purpose for three of them: the D-alanine at position 2, because peptides with D-alanine there resist the enzyme DPP-4, and the changes at positions 8 and 27, to prevent chemical breakdown of the residues they replace. How much the swaps add to stability has not been determined, and FDA says a demonstration that the DAC form outlasts the form without DAC would be needed to show that the linker is what makes it last. The albumin linker is still the single feature that splits CJC-1295 into two drugs.

CJC-1295 came from ConjuChem Biotechnologies, a Montreal company whose whole platform was clipping short-lived drugs onto albumin. Its lead GHRH candidate, built on the 29-residue core of the hormone characterized from a human pancreatic tumor in 1982, produced days-long GH and IGF-1 elevation in early human studies, an impressive result. Then a patient in the phase II trial died of a cardiovascular event, the study was halted, and the company ended development. The card pairs the promise with that abrupt stop.

The honest reading is careful on both sides. The early human data are real and show genuine pharmacology, but the phase II death, whose relationship to the drug was still under investigation when the trial stopped, ended the program before any efficacy result was published. What we are left with is a promising short chapter, not a finished book: FDA's 2024 review found no study in which any form of CJC-1295 was given to people with a disease or condition.

If you remember one thing from this course, make it this: CJC-1295 with DAC and CJC-1295 without DAC are not two doses of the same drug, they are two different drugs. The DAC version was measured in healthy adults, where its half-life was estimated at 5.8 to 8.1 days. The no-DAC version has never had its half-life measured in anyone, and FDA reports that it could find no study establishing that the molecule is pharmacologically active at all. The two panels put them side by side so the gap is unmistakable.

This is not a pedantic footnote. FDA counts five distinct substances under the name CJC-1295, split across two different active moieties, and at least nine names used for those five over the years. It calls that confusion a safety risk in its own right, because a patient may be dosed with a different substance than the physician ordered. Every pharmacology and safety statement later in the course is tagged by variant for exactly this reason.

CJC-1295 sits in an unusual spot: its short-term pharmacology was measured, but almost everything people actually want it for, body composition and long-term benefit, was not. The three human studies FDA reviewed were small, short studies in healthy adults that measured hormone levels, not those outcomes. The tiers below separate what is measured from what is merely hoped, and the gauge scores the flagship claim.

The gap between the top tier and the bottom is the entire point. The pharmacology is real and the mechanism is coherent, but the leap from a documented hormone rise to a promised physical outcome is exactly where the evidence runs out. Keeping those apart is what separates honest education from marketing copy for this drug.

A handful of confident claims dominate the online conversation about CJC-1295. Held against the evidence, most are not flatly false so much as overstated: a real short-term effect gets rounded up into a guaranteed outcome. Tap each claim to see the honest verdict and its evidence tier.

Notice the recurring pattern. The strongest claim, days-long IGF-1 elevation, is exactly the one with trial data behind it, while the popular muscle-and-safety claims are the ones running ahead of the evidence. Learning to attach the right tier to each statement is the core skill this course builds.